

## STATE OF WASHINGTON HEALTH CARE AUTHORITY

626 8th Avenue, SE • P.O. Box 45502 • Olympia, Washington 98504-5502

July 6, 2022

SUBJECT: UPDATE TO HEALTH TECHNOLOGY ASSESSMENT TOPIC SELECTION, 2022

**Hyaluronic acid and platelet-rich plasma (PRP)** were originally reviewed by the Health Technology Clinical Committee (HTCC) in 2013 and 2016, respectively. I have selected these topics for re-review by the HTCC.

As the Director of the Health Care Authority, I select technologies for review by the HTCC in consultation with participating agencies and the Committee itself (70.14 RCW). Technologies are selected for re-review when there is new information that could change a previous determination.

Studies have been published since the previous reviews that may impact those determinations.

Upon publication of this notice to grant the petition to re-review **hyaluronic acid & PRP**, a 30-day comment period will begin whereby any interested person or group may provide information to be considered in the review of the selected topic.

Should you have any questions or concerns, please contact the HTA Program via email at <a href="mailto:shtap@hca.wa.gov">shtap@hca.wa.gov</a>.

Sincerely,

Susan E. Birch, MBA, BSN, RN

Director

By email